Takeda and Alkermes at #WorldSleep2025 Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 8 September, 2025

Endpoints News returns to Boston’s State Room to announce the 2025 class of biotechs worth watching. Join the live unveiling and see the industry’s next chapter come into focus. Which biotechs will make the leap? Join us.

presented by The new blue­print for biotech: RNA edit­ing and ra­di­oli­gand ther­a­py

news Summit says long-awaited data in Western patients are a success. But they come with caveats Rapport reveals promising open-label study data for epilepsy pill, heads to Phase 3 Biotech vet Harvey Berger steps into CEO role at Arena BioWorks, as billionaire-backed R&D center retools Alkermes’ success in Phase 2 narcolepsy trial is clouded by side effects •  Takeda’s Phase 3 narcolepsy results could make it first mover in multibillion-dollar market Servier buys Medicxi startup's fragile X candidate for up to $450M A British mitochondrial startup wants to break ground in ALS and Parkinson's. It has £50M to try

Sep 09 11:30am ET How ctDNA can assist in critical nonoperative management decisions sponsored by Haystack MRD Sep 23 11:00am ET Data you can trust: Setting the bar for ML/LLM-extracted real-world data sponsored by Flatiron Sep 25 11:00am ET Leveraging acoustic focusing for fast and precise high-parameter flow cytometry panels sponsored by Thermo Fisher Oct 02 10:30am ET Unlocking patient access: Modernizing clinical trial regulatory frameworks and trial delivery sponsored by Lilly Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

ESMO 2025's most critical readouts are coming — join our post-conference recap to decode what the data means for your pipeline. Register now.

ENDPOINTS PHARMA FDA chief details ‘intense investigation’ into alleged child deaths from Covid-19 shots FDA is readying more surprise inspections for foreign drug sites, Makary says Japan-made generic drugs will be exempt from Trump’s reciprocal tariff

in case you missed it 1. WHO adds GLP-1s to essential medicines list 2. Updated: Hengrui does another US deal, this time in Cytokinetics' cardio arena 3. Peer Review Merck KGaA finds its next R&D leader; Exelixis retools management team as medical chief leaves